drug

enasidenib mesylate

Marketedupdated 2mo ago

by Bristol-Myers Squibb Co

Approved

community read0 votes

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

Data sources

ClinicalTrials.gov

last refreshed 1h ago

Found something off?

Patent cliff

source: FDA Orange Book

first barrier falls

Jun 21, 2030

~4.0 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (12)

Sep 16, 2034compositionUS 9732062
Sep 16, 2034compositionUS 9732062
Aug 1, 2034compositionUS 10093654
Aug 1, 2034compositionUS 10093654
Aug 1, 2034compositionUS 9738625
Aug 1, 2034compositionUS 9738625
Jan 7, 2033formulationUS 10294215
Jan 7, 2033formulationUS 10294215
Jan 7, 2033compositionUS 9512107
Jan 7, 2033compositionUS 9512107
Jun 21, 2030method-of-use (U-2087)US 106101254.0y
Jun 21, 2030method-of-use (U-2087)US 106101254.0y

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Trials studying enasidenib mesylate

phase2CPX-351 Plus Enasidenib for Relapsed AMLactive not recruitingn=2